![]() ![]() Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical Suchįorward-looking statements include statements regarding, among other things, Silverbacks ability to bring new treatments to patients in need, and the progress and expected timing of Silverbacks drug development programs and clinical ![]() To learn more, visit Forward-Looking StatementsĬertain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Silverback Therapeutics is located in Seattle, Washington. Solid tumors to promote cancer cell killing. ![]() Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in Modifying pathways with monoclonal antibodies directed at specific disease sites. Silverbacks platform enables the strategic pairing of proprietary payloads that modulate key disease Systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop It is an important time for our industry as we bring forward more drugs with curative intent, and I am thrilled to join a passionate board of directors Responses, is an elegant approach to treating solid tumors, said Dr. Koehler. Silverbacks pipeline of tissue-targeted immuno-oncology agents, which harnesses both innate and adaptive immune from the Silesian Medical School in Poland and has co-authored over 150 publications, book Prior to Bicycle, she was Vice President of Strategy and Innovation for Pfizer Oncology, where she led the development of palbociclib (IBRANCE)Īnd contributed to the strategic direction of the oncology portfolio. Prior to joining Repare, Dr. Koehler was Chief Medical Officer at Bicycle Therapeutics. Dr. Koehler currently serves as the Chief Medical Officer at Repare Therapeutics, leading clinical strategy and overseeing all Global markets, having developed strategies for all stages of cancer drug development and medical affairs. Board certified in hematology/oncology, she has experience in both early drug development and bringing new drugs to Her leadership and clinical experience will be invaluable at this stage of Silverbacks growth, as weĪdvance our lead program SBT6050 through clinical development and drive additional assets into the clinic.īoard of Directors with more than 20 years of experience in the biopharmaceutical industry as a leader in clinical development. Maria is an accomplishedīiopharmaceutical veteran who has led world-class clinical development teams that have delivered transformative therapies to cancer patients. Senior management team at Silverback, I am pleased to welcome Maria to the board, said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. ![]() Today announced the appointment of Maria Koehler, M.D., Ph.D. (Nasdaq: SBTX) (Silverback), aĬlinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, SEATTLE Ma Silverback Therapeutics, Inc. Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |